Health and Healthcare
New Cellulite Study Submission Could Be a Big Hit
Published:
Last Updated:
Endo International PLC (NASDAQ: ENDP) shares jumped on Friday after the company announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.
The submission is based on positive results from two identical Phase 3 Release studies that were presented at the 2019 Annual Meeting of the American Academy of Dermatology and subsequently at the Aesthetic Meeting 2019.
A greater percentage of the 843 women treated during the studies met the primary endpoint of response with CCH versus placebo in both the Release-1 and Release-2 studies.
Additionally, statistically significant improvements with CCH versus placebo were observed for eight of eight (Release-1) and seven of eight (Release-2) secondary endpoints. All patient-centric endpoints, evaluated using validated patient-reported scales like Patient Reported Photonumeric Cellulite Severity Scale, Subject Global Aesthetic Improvement Scale, Patient Reported Cellulite Impact Score and Subject Self Rating Scale, showed statistically significant improvement in the CCH group when compared to the placebo group.
Most adverse events observed in CCH-treated patients were transient, mild to moderate and injection-site related.
The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. Endo will communicate the FDA’s decision.
Shares of Endo traded up about 19% on Friday to $2.82, in a 52-week range of $1.97 to $18.50. The consensus price target is $5.47.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
